{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-013059","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.717105+00:00","generated_at":"2026-06-19T06:43:26.021052+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Actinium announces positive Phase 3 SIERRA trial results for Iomab-B in r/r AML","bullets":["Iomab-B met primary endpoint: 22% durable CR vs 0% control (p<0.0001).","Event-free survival HR=0.22 (78% risk reduction, p<0.0001).","Iomab-B doubled 1-year OS (26.1% vs 13.1%) and median OS (6.4 vs 3.2 months).","Sepsis rate 4x lower (6.1% vs 28.6%); 100% engraftment in Iomab-B arm.","Patients achieving dCR had 92% 1-year and 60% 2-year survival."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-013059","json":"https://secwatch.observer/filing/0001213900-23-013059.json","markdown":"https://secwatch.observer/filing/0001213900-23-013059.md","text":"https://secwatch.observer/filing/0001213900-23-013059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390023013059/0001213900-23-013059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390023013059/ea173990-8k_actinium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:43:26.021052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}